Lynchburg Journal of Medical Science
Dr. Tom Colletti, DHSs, MPAS, PA-C, DFAAPA
Obesity has quickly become a leading health crisis in the United States. When patients, without a medical condition, causing their obesity, have attempted to lose weight through a better diet, or increased exercise, and failed, anti-obesity therapy should be the next step in the treatment. Currently, only eleven anti-obesity medications have been approved by the FDA, with the majority of the medications being approved within the last 10 years. The six medications that are approved for long-term use are Orlistat (Alli), Phentermine-Topiramate (Qsymia), Bupropion-Naltrexone (Contrave), and GLP-1s that include Liraglutide (Saxenda), Setmelanotide (Imciveree), and Semaglutide (Wegovy). All 4 anti-obesity medications approved for short-term use are sympathomimetics including Phentermine (Adipex), Diethylpropion (Tepanil), Phendimetrazine (Adipost), and Benzphetamine (Didrex). This article will discuss the mechanism of action, indications, efficacy, and side effects of each medication, and the future of anti-obesity medications will be examined.
Peters NP. A Review of Antiobesity Drug Therapy. Lynchburg Journal of Medical Science. 2023; 5(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.